US FDA approves Amgen leukemia drug ahead of schedule
Dec 3 (Reuters) - U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date. The drug, blinatumomab, which will be sold under ...
Amgen snags a lightning-fast approval for its leukemia immunotherapyFierceBiotech
FDA clears Amgen blood cancer immunotherapy (AMGN)Seeking Alpha
Amgen Wins U.S. Approval for Immunotherapy Against LeukemiaTheStreet.com
FDA.gov -OncLive -Pharmacy Times
all 7 news articles »